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Abstract
Background:Multiple sclerosis is often associated with unemployment. The contribution of grey matter
atrophy to unemployment is unclear.
Objectives: To identify magnetic resonance imaging biomarkers of grey matter and clinical symptoms
associated with unemployment in multiple sclerosis patients.
Methods: Demographic, clinical data and 1.5 T magnetic resonance imaging scans were collected in 81
patients at the time of inclusion and after 5 and 10 years. Global and tissue-specific volumes were
calculated at each time point. Statistical analysis was performed using a mixed linear model.
Results: At baseline 31 (38%) of the patients were unemployed, at 5-year follow-up 44 (59%) and at
10-year follow-up 34 (81%) were unemployed. The unemployed patients had significantly lower sub-
cortical deep grey matter volume (P< 0.001), specifically thalamus, pallidus, putamen and hippocampal
volumes, and cortical volume (P¼ 0.011); and significantly greater T1 (P< 0.001)/T2 (P< 0.001)
lesion volume than the employed patient group at baseline. Subcortical deep grey matter volumes,
and to a lesser degree cortical volume, were significantly associated with unemployment throughout
the follow-up.
Conclusion:We found significantly greater atrophy of subcortical deep grey matter and cortical volume
at baseline and during follow-up in the unemployed patient group. Atrophy of subcortical deep grey
matter showed a stronger association to unemployment than atrophy of cortical volume during the
follow-up.
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Introduction
Multiple sclerosis (MS) is a chronic, debilitating dis-
ease of the central nervous system. The disease onset
is typically in young adulthood in patients’ most
vulnerable years, when obtaining an education, start-
ing a family and establishing a career are key events
in life. Employment status is an important part of the
comprehensive assessment and unemployment is a
considerable issue for MS patients. A large cross-
sectional study conducted in 16 European countries
showed that only approximately 50% of MS patients
below retirement age were employed.1 Several stud-
ies have explored the clinical determinants of work-
related problems and unemployment,2–5 but
magnetic resonance imaging (MRI) pathology relat-
ed to unemployment has been scarcely explored.
Studies by Kadrnozkova et al.6 and Tauhid et al.7
thoroughly explore the relationship between lesion
volumes, brain atrophy and employment status
cross-sectionally and longitudinally, respectively.
The cross-sectional study found increased lesion
volume, increased T1 lesion volume and increased
burden of T2 lesions showing T1 hypointensity, and
decreased whole brain volume, all significantly asso-
ciated with unemployment. Longitudinally, whole
brain atrophy, T1 and T2 lesion load were predictors
of unemployment after 12 years.6 Further studies on
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this topic are warranted for the better understanding
of unemployment in MS patients.
Traditionally, MS has been regarded as a disease of
the white matter with multifocal lesions, evident by
T2 hyperintense and T1 hypointense MRI lesions,
causing axonal damage, and thereby leading to phys-
ical impairment. Extensive research during the past
decades has greatly increased our knowledge of the
pathomechanisms and symptoms of the disease.
MS is not exclusively an inflammatory disease, as
neurodegeneration and atrophy are apparent from
the earliest stages of the disease.8 The involvement
of grey matter pathology is evident, contributing to
both physical and cognitive impairment. The burden
of physical and cognitive impairment affects the
patients’ total life situation profoundly, in which
loss of employment is one of the consequences.9
Brain atrophy is increasingly used as a marker of
disease activity in research.10 and regional and
tissue-specific atrophy of the deep grey matter have
been shown to correlate with clinical symptoms in
several studies.11,12 The association between subcor-
tical deep grey matter (SDGM) atrophy and clinical
disability has been shown in several studies.9,12–15
The aim of this paper was to investigate the relation-
ship between grey matter atrophy and occupational
status in MS patients cross-sectionally and over 5
and 10 years, and explore the effect of common
MS symptoms on employment status over 5 and
10 years. Our hypothesis was that subcortical deep




All patients diagnosed with MS in the south western
parts of Norway in the years of 1998 to 2000 were
invited to participate in the study, and were included
at the time of diagnosis. The study population is
described in an earlier paper.13 The diagnosis of
MS was made according to the current diagnostic
criteria at that time, the criteria of Poser et al.16
We identified 108 patients eligible for inclusion,
three of them had moved elsewhere, one had died
and 11 declined participation, leaving 93 patients.
From those, 81 patients went through the necessary
testing, neurological examination and MRI of the
brain, and were subsequently included in the study
(Figure 1).
Follow-up assessments were performed after 5 and
10 years, and included clinical assessment and MRI
of the brain.
At each time point, information regarding demo-
graphics, employment status, medical history and
medication was collected. Clinical neurological
examination with evaluation of the Kurtzke
Expanded Disability Status Scale (EDSS) and cog-
nitive testing using the symbol digit modalities test
(SDMT) were performed at 5 and 10 years’ follow-
up. We investigated fatigue using the fatigue sever-
ity scale (FSS) at each time point.
The study was approved by the regional committee
for medical and health research of western Norway
and the Norwegian Data Protection Authority.
Written informed consent was collected from all
patients in accordance with the Helsinki Convention.
MRI acquisition and analysis
MRI scans were performed at 1.5 T (Siemens,
Symphony/Philips Medical systems, Intera) units,
in two different centers; at Haukeland University
Hospital in Bergen and Stavanger University
Hospital in Stavanger. The MRI protocol included
a dual spin echo (SE) proton density (PD)/T2 weight-
ed image (WI), a three-dimensional (3D) T1 WI and a
SE T1 WI. On the Siemens scanner the voxel size
for (SE) PD/T2 WI was 0.9 0.9 5.0mm3, for 3D
Figure 1. Flow chart of patient inclusion at baseline, 5-year and 10-year follow-up.
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T1 WI 0.9 0.9 1.4mm3 and for SE T1 0.9
0.9 5.0mm3. On the Philips scanner the voxel
size for (SE) PD/T2 WI was 0.89 0.895.0mm3,
for 3D T1 WI 0.89 0.89 1.2mm3 and for SE T1
0.89 0.89 5.0mm3.
The protocol is described in detail elsewhere.13
Furthermore, the MRI scans were subsequently ana-
lyzed in order to calculate global and tissue-specific
atrophy measures and lesion volumes. All baseline
and follow-up images for a given subject were
co-registered to its baseline T1 SE image using
FMIRIB’s FLIRT (FMRIB’s linear image registra-
tion tool). Using co-registered images, T1 and T2
lesion volumes were calculated using a reliable
semi-automated edge detection contouring/thresh-
olding technique previously described.17 The 3D
T1 scans were first inpainted to minimize the
impact of white matter lesions on grey matter
volume measurements.18 The normalized cortical
volume was measured using SIENAX (V 2.6) as
previously described.19,20 For deriving cortical vol-
umes at the follow-up time points, the SIENAX-
MTP method was utilized.21 Absolute volumes of
the subcortical deep grey structures were estimated
from inpainted 3D T1 images with FMRIB’s inte-
grated registration and segmentation tool (FIRST
V1.2), a model-based segmentation/registration
tool.22 Normalized SDGM volumes were obtained
by multiplying the estimated volumes from FIRST
by the volumetric scaling factor from SIENAX.19
The process is described in detail elsewhere.13
Employment status assessment
At each time point employment status was assessed.
We categorized the patients as employed or unem-
ployed, including part time employment in the
employed patient group. The patients were catego-
rized as unemployed at the time when they received
disability pension and permanently exited the work
force. In Norway, during the time of inclusion and
follow-up, being granted disability pension was a
permanent decision.
Statistical analysis
Descriptive statistics are presented as means and
standard deviations (SDs), medians and interquartile
ranges (IQRs), or as counts and percentages for con-
tinuous symmetric, continuous non-symmetric and
categorical data, respectively. Between-groups com-
parisons were correspondingly performed using
independent samples t tests, Mann–Whitney rank
sum tests, or chi-square tests. The association
between MRI characteristics and risk of unemploy-
ment were studied using generalized estimating
equations (GEEs) logistic regression, with AR(1)
working correlation and robust estimation of stan-
dard errors. Years of follow-up were included in
the models as a continuous covariate, and adjust-
ments were made for demographic (age, sex, study
center and level of education) and clinical variables
(MS course). Furthermore, cognition, fatigue and
EDSS scores were included in the Supplementary
analyses. For the patients employed at baseline, the
association between unemployment at 5 and 10-year
follow-up and, respectively, MRI volumes at base-
line and percentage brain volume change between
baseline and follow-up were investigated.
Results are presented as odds ratios (ORs) with 95%
confidence intervals (CIs), and with P values for the
Wald tests of null effects.
All statistical analyses were performed using SPSS
v. 24. Results with P values of 0.05 or less were
considered statistically significant.
Results
Demographic, clinical and MRI characteristics at
baseline
Demographic, clinical and MRI characteristics of the
cohort at baseline, 5 and 10-year follow-up are
shown in Table 1. At baseline, 31 of 81 (38%,
95% CI 0.28–0.50%) patients were unemployed.
At the 5-year follow-up this number had increased
to 44 of 75 (59%, 0.47–0.70%), and at the 10-year
follow-up altogether 34 of 42 (81%, 0.35–0.91%)
were unemployed.
Between baseline and the 5-year follow-up 18
patients became unemployed. Between the 5-year
and 10-year follow-up four patients became unem-
ployed. In the employed patient group there was a
drop-out of 19 patients at the 10-year follow-up, and
in the unemployed patient group there was a drop-
out of 14 patients.
When comparing the employed and unemployed
patient groups at baseline we found the unemployed
patient group was older, having a higher EDSS
score, longer disease duration, having more fatigue
and cognitive impairment, higher T1/T2 lesion vol-




MRI and clinical variables associated with
employment status
We investigated MRI and clinical variables affecting
employment status, specifically the cortical grey
matter and the subcortical grey matter. Furthermore,
we separately investigated the different deep grey
matter structures.
The total effect of SDGM volume over the 10-year
follow-up, when adjusting for age, sex, MS course,
level of education and study center, was estimated
as OR 0.87 (95% CI 0.80–0.95; P¼ 0.002), i.e.
for every one cm3 higher subcortical volume, the
odds of being unemployed was reduced by 13%
(Table 2). After adjusting for cognitive impairment
(SDMT), fatigue (FSS) and physical disability
(EDSS), the association was weaker and not signif-
icant (P¼ 0.11) see Supplementary Table 1).
Of the individual subcortical structures, all except
for the caudate showed a significant effect on unem-
ployment when adjusting for age, sex, MS course,
level of education and study center. After adjusting
for cognitive impairment, fatigue and physical dis-
ability, we found the atrophy to be mostly mediated
through cognitive function and physical disability
(see Supplementary Table 1).
When adjusting for SDMT, FSS and EDSS, only
lower hippocampus volume showed a significant
remaining effect on unemployment, with OR 0.59
(95% CI 0.38–0.93; P¼ 0.021) (Table 2).
The total effect of cortical volume over the 10-year
follow-up, when adjusting for age, sex, MS course,
level of education and study center, was estimated as
OR 0.99 (95% CI 0.97–1.0; P¼ 0.045), i.e. for
every one cm3 higher cortical volume, the odds of
being unemployed was reduced by 1%. After adjust-
ing for cognitive impairment (SDMT), fatigue (FSS)
and physical disability (EDSS), the association was
weaker and not significant (P¼ 0.51) (Table 2).
Discussion
This prospective, longitudinal study of a cohort
of MS patients identifies MRI markers of grey
matter and associated clinical symptoms contribut-
ing to unemployment. SDGM atrophy showed the
strongest association with unemployment, whereas
cortical atrophy showed a weaker, yet significant
relationship with employment status. Of the SDGM
structures, lower volumes of thalamus, pallidus,
putamen and hippocampus were associated with
unemployment. This is in line with a cross-
sectional study of 50 relapsing–remitting MS






P valueUnemployed Employed P value Employed Unemployed Employed
No. of patients (%) 31 (38.3) 50 (61.7) 44 (58.7) 31 (41.3) 34 (81.0) 8 (19.0)
Age mean (SD) 47.3 (8.7) 38.3 (8.3) <0.001 48.2 (9.4) 43.6 (8.8) 0.035 54.0 (9.2) 47.1 (6.8) 0.071
Women, n (%) 22 (71.0) 33 (66.0) 0.81 33 (75.0) 19 (61.3) 0.22 26 (76.5) 7 (87,5) 0.66

























in months, mean (SD)
134.0 (103.1) 76.0 (70.5) 0.002 163.8 (95.0) 149.0 (87.0) 0.51 230.6 (113.0) 193.2 (87.7) 0.66
DMT use, n (%) 3 (9.7) 8 (16) 0.42 19 (43.2) 14 (45.1) 0.87 23 (67.6) 6 (75.0) 0.69
FSS, mean (SD) 5.5 (1.7) 4.5 (1.7) 0.003 5.6 (1.3) 4.4 (1.9) 0.003 5.4 (1.5) 4.7 (1.3) 0.13
SDMT, mean (SD) 36.8 (11.3) 45.4 (12.6) 0.002 35.8 (13.4) 49.3 (12.1) <0.001 39.3 (15.4) 55.5 (10.8) 0.004
Cortical volume 559 (557) [557] 585 (41.2) [582] 0.011 551 (46.9) [551] 577 (31.8) [574] 0.013 548 (39.8) [552] 534 (47.6) [517] 0.49
SDGM volume 42.1 (5.4) [40.3] 46.4 (5.0) [46.3] <0.001 41.0 (6.2) [40.2] 45.6 (5.3) [45.6] 0.003 41.5 (6.0) [41.2] 43.3 (3.5) [41] 0.53
T2 LV, median (IQR) 17.3 (22.6) 6.22 (12.2) <0.001 21.0 (25.9) 5.41 (14.4) 0.002 15.5 (17.4) 4.24 (6.0) 0.025
T1 LV, median (IQR) 6.9 (11.7) 1.9 (3.9) <0.001 7.3 (14.1) 1.7 (4.5) 0.002 3.4 (8.9) 0.2 (1.9) 0.034
Brain volumes are presented in millilitres as mean, (SD), [median].
The differences between the employed and unemployed groups were calculated using Student’s t test and Mann–Whitney rank sum test, as
appropriate.
EDSS: Expanded Disability Status Scale; MS: multiple sclerosis; RR: relapsing–remitting; SP: secondary progressive; PP: primary progres-
sive; DMT: disease-modifying therapy; FSS: fatigue severity score; SDMT: symbol digit modalities test; SDGM: subcortical deep grey matter;
LV: lesion volume.
Note. Bold values denote statistical significance at the p < 0.05 level.
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patients showing significantly more thalamic atro-
phy in unemployed patients.9
Some cross-sectional studies have explored the cor-
relation between MRI biomarkers and employment,
and both lesion load, whole brain volume and central
atrophy were associated with unemployment.7,9
However, only a handful have explored the contri-
bution of brain atrophy to unemployment longitudi-
nally.6 This paper can be viewed as an important
addition to the current knowledge, exploring the
role of brain atrophy in more detail. To the best of
our knowledge, this paper is one of the first to
explore the relationship between brain atrophy of
the SDGM structures and employment status longi-
tudinally. Compared to SDGM atrophy, a weaker
association was seen between cortical atrophy and
unemployment in our study. This is in line with
several studies concluding with atrophy of the
deep grey matter being strongly associated with dis-
ability12,13,23 and cognitive impairment.9,14 Cortical
atrophy has in several studies been found to be asso-
ciated with clinical symptoms, namely cognitive
dysfunction11 and neurological disability.13 The
underlying pathology causing deep grey matter atro-
phy is not fully understood, and several mechanisms
are probably present. Most of the deep grey matter
regions are central hubs with widespread connec-
tions to several regions of the brain, including the
cortex, making them especially vulnerable.
We found an unemployment rate of 38.3% at base-
line, and the unemployment rate increased over the
10-year follow-up. The proportion of unemployed
MS patients varies considerably in different studies.
In a recent study with almost 17,000 patients in 16
European countries, the proportion of patients not
employed due to MS was between 20% and
64%,1 and a recent meta-analysis found an average
employment rate of 44% across 33 cross-sectional
studies. The great difference in reported unemploy-
ment is most likely caused by different patient
groups (hospital vs. outpatient clinic), different diag-
nostic criteria used, disease duration and social ser-
vice systems. In comparison, overall 7.8% of the
population aged 18–67 years in the county of
Rogaland were receiving disability pension in the
year 2015.24 Hence, MS affects the employment
ability profoundly in western Norway.
Clinical correlates of unemployment are well
explored in several studies, showing unemployed
patients having more physical disability, cognitive
impairment, depression and fatigue, and lower qual-
ity of life.2–5,25,26
SDMT is as a measure of processing speed, and we
chose it as a measure for cognitive impairment, as it
has been shown to be a valid and reliable method to
measure cognitive impairment in MS patients.27,28
The unemployed patients had a significantly worse
SDMT score compared to the employed group at
baseline and 5-year follow-up. In the GEE analysis,
worsening processing speed, as measured by SDMT,
was the clinical parameter best associated with
unemployment. This is in line with a study con-
ducted on 60 relapsing–remitting MS patients show-
ing decreased volumes of thalamus, hippocampus
and putamen being associated with reduced cogni-
tive performance, especially in terms of processing
speed.15
Fatigue was significantly more pronounced in the
unemployed patient group at baseline and 5-year
Table 2. GEE model parameter estimates.
Model Unadjusted Model A Model B Model C
Predictor n/obs OR (95% CI) P value n/obs OR (95% CI) P value n/obs OR (95% CI) P value n/obs OR (95% CI) P value
Cortical 81/173 0.98 (0.97, 1.00) 0.003 76/163 0.99 (0.97, 1.00) 0.037 76/161 0.99 (0.97, 1.00) 0.045 74/146 1.00 (0.98, 1.01) 0.51
Subcortical 81/173 0.87 (0.82, 0.94) <0.001 76/163 0.87 (0.80, 0.95) 0.001 76/161 0.87 (0.80, 0.95) 0.002 74/147 0.93 (0.84, 1.02) 0.11
Thalamus 81/173 0.71 (0.58, 0.87) 0.001 76/163 0.68 (0.52, 0.89) 0.005 76/161 0.68 (0.51, 0.89) 0.006 74/147 0.81 (0.59, 1.11) 0.19
Pallidus 81/173 0.29 (0.13, 0.63) 0.002 76/163 0.22 (0.09, 0.53) 0.001 76/161 0.24 (0.10, 0.58) 0.002 74/147 0.43 (0.14, 1.38) 0.16
Putamen 81/173 0.57 (0.44, 0.75) <0.001 76/163 0.61 (0.46, 0.83) 0.001 76/161 0.61 (0.45, 0.83) 0.002 74/147 0.73 (0.50, 1.05) 0.090
Caudate 81/173 0.60 (0.39, 0.91) 0.017 76/163 0.68 (0.41, 1.15) 0.15 76/161 0.67 (0.40, 1.15) 0.15 74/147 0.93 (0.51, 1.69) 0.80
Hippocampus 81/173 0.44 (0.28, 0.68) <0.001 76/163 0.47 (0.30, 0.74) 0.001 76/161 0.48 (0.31, 0.76) 0.002 74/147 0.59 (0.38, 0.93) 0.021
Model A: adjusted for baseline covariates: center, sex, age and education.
Model B: adjusted for baseline covariates: center, sex, age and education; and time-varying MS course.
Model C: adjusted for baseline covariates: center, sex, age and education; time-varying MS course; and time-varying symbol digit modalities
test, fatigue severity score and Expanded Disability Status Scale.
GEE: general estimating equation; OR: odds ratio; CI: confidence interval; MS: multiple sclerosis.
Note. Bold values denote statistical significance at the p< 0.05 level.
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follow-up. We found that fatigue to some extent was
explained by loss of SDGM volume. Other papers
have suggested that the basal ganglia partly contribute
to fatigue.29 A recent systematic review suggested
that the cortico-striato-thalamo-cortical loop has
close connections with the development of central
fatigue.30
Disability, as measured by EDSS, was significantly
more pronounced in the unemployed patient group at
all time points. A higher EDSS, suggestive of greater
physical disability, was in our findings to some
extent explained by loss of SDGM volume, in
particular thalamus, putamen and hippocampus
volumes. Several studies have shown an association
between grey matter atrophy and physical disabili-
ty,13,23 and the contribution of physical disability to
unemployment is well established.5,31–33
The greatest strength of this paper is that we were
able to follow an unselected cohort of patients newly
diagnosed with MS over 10 years. It is of interest
that the patients were largely untreated in the first
part of the follow-up, thus providing insight into the
evolution of atrophy in absence of the newer, more
efficient treatment options.
This study has some limitations. We had a relatively
small sample size, and a considerable drop-out of 30
patients over the 10-year follow-up. At the 10-year
follow-up a considerable drop-out of 61% of the
group employed at 5 years, compared to a drop-out
of 31% of the patients that were unemployed at the
5-year follow-up. Hence, caution should be exercised
when interpreting the 10-year follow-up results. The
MRI was performed by two different scanners, but
when detecting longitudinal volume changes the
effect of different scanners is rather small.34 We nev-
ertheless adjusted for center in the statistical analysis
to account for this issue. Moreover, all scans were
acquired on 1.5 T MRI systems, whereas 3T acquis-
itions may result in somewhat more reliable volumet-
ric segmentations.35
We categorized the patients as unemployed at the
time of receiving disability pension. This is a strict
definition, and the majority of these patients were
completely or partly unable to perform paid work
before disability pension was granted. However,
this represents the time point the patient is found
permanently unfit to continue work on the basis of
a thorough evaluation. Unfortunately, our data do
not differentiate whether other conditions contribut-
ed to the patients becoming unable to perform paid
work. The unemployed patient group was on average
9 years older than the employed patients. Knowing
the effect of age on brain atrophy and clinical symp-
toms, the effect on our results is difficult to account
for fully in the analysis, and should be taken into
consideration when interpreting the results.
Employment has been proposed as a comprehensive
marker of the function and wellbeing of MS
patients.31 Being employed is associated with great-
er quality of life in several studies. Depression is
shown to be associated with unemployment, and is
suggested to be a result of, rather than causing,
unemployment.26 Current markers, such as disability
measures like EDSS, used to monitor disease pro-
gression and severity of disease are at best inade-
quate. The state of employment can provide added
information on the level of function of MS-patients.
MRI markers that can help detect patients at risk of
exiting the workforce are useful, as proactive inter-
vention can possibly aid in preventing, or at least
delaying, unemployment. In the future, in our opin-
ion, the detection of deep grey matter atrophy will
possibly be a marker for disease activity, prompting
early, efficacious disease-modifying treatment. The
predictive value of SDGM atrophy on later unem-
ployment would be of interest to explore, unfortu-
nately a lack of statistical strength did not allow us to
perform these analyses.
Conclusion
Atrophy of the SDGM structures showed a strong
association with unemployment, whereas a weaker
association was seen with cortical atrophy. As atro-
phy starts early in the disease course, an early focus
on measures to keep MS patients in the workforce is
warranted.
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